Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Further Reading from MarketBeat 3 Stocks You'll Wish You Bought Before 2026Written by Chris Markoch. Published 12/3/2025. 
Key Points - These three up-and-coming stocks have delivered triple-digit gains in 2025 and continue to show strong momentum.
- Key catalysts—including clinical milestones, revenue acceleration, and consumer demand—suggest more upside ahead.
- Analysts stay optimistic, with price targets suggesting possible double- or triple-digit gains from current levels.
Many investors have profited from the artificial intelligence (AI) trade in 2025, but several up-and-coming stocks in other sectors have also posted impressive gains this year. The three stocks in this article are still small-cap — the largest market cap among them is just over $4 billion — yet each has made strong moves and reinforced the idea that time in the market is often better than trying to time the market. Most investors fixate on every word from the Federal Reserve. But a quieter shift in Washington could matter far more for the future of U.S. monetary policy — and for assets like gold.
A veteran analyst argues that upcoming changes at the Fed may reshape the landscape in ways the market isn't fully pricing in yet. In a recent briefing, he explains why this shift could reignite interest in overlooked gold opportunities, and shares what he uncovered during an unexpected trip to a Colorado ski town. See the full analysis here If investors could see the future with perfect clarity, investing would be easy. Unfortunately, the future is rarely clear and a bullish outcome is not guaranteed. Still, the charts speak for themselves: investors who bought these stocks and had the patience to hold through rough patches are being rewarded today, and the rallies may not be finished. Biotech Breakthrough: A Small Cap With a Big 2026 FDA Catalyst Celcuity Inc. (NASDAQ: CELC) is a clinical-stage biotechnology company that recently reported positive data for its first-in-class PI3K/mTOR inhibitor targeting HR+/HER2- metastatic breast cancer. The company's pivotal Phase 3 VIKTORIA trial is underway, and some investors believe Celcuity could receive U.S. Food & Drug Administration (FDA) approval in 2026. Investors have been front-running those expectations, pushing CELC stock up more than 660%, with nearly all of that gain occurring since the end of July. At $99.30 as of this writing, the stock sits within roughly 3% of its consensus price target. On Dec. 2, Jefferies raised its price target on the stock to $134 from $108. The primary risk is the cost of commercialization. However, in its most recent earnings report, Celcuity showed a reinforced balance sheet with $455 million in cash, cash equivalents, and short-term investments — about a 72% increase year-over-year (YOY) — and management believes that cash will be sufficient through the commercialization transition. Fintech Disruptor Turning Revenue Growth Into Real Momentum At a time when many banks offer less to everyday consumers, it's easy to make the case for Dave Inc. (NASDAQ: DAVE), the Los Angeles-based fintech behind the Dave app. The Dave app provides affordable, transparent financial tools that help users — many living paycheck to paycheck — avoid overdraft fees, budget more effectively, and access short-term cash when needed. The company recently reported a 64% YOY increase in revenue and an 85% beat in adjusted earnings per share (EPS). DAVE stock is up about 120% in 2025, and analysts see more upside. Trading near $208.24 as of this writing, the consensus price target is $304.25 — more than 46% higher. Some investors may be wary of the company's forward price-to-earnings (P/E) ratio of roughly 119x. But analysts are forecasting earnings growth of over 117% in the next 12 months, which could justify expansion into that valuation if executed. Resale Retail Winner Riding a Massive Consumer Shift It's been another difficult year for consumer staples stocks, but ThredUP Inc. (NASDAQ: TDUP) has been a notable exception. TDUP stock is up more than 430% in 2025, despite a roughly 29% sell-off in the three months ending Dec. 1. The company operates an online consignment marketplace, which positions it well as many consumer budgets remain stretched. The thrift and resale market was a $49 billion industry in 2024 and is expected to grow to $74 billion by 2029. TDUP is the smallest of the three names on this list, and short interest above 17% indicates active trading and skepticism. Still, the company's Q3 report showed strong YOY revenue growth, a record number of new buyers acquired, and a 37% YOY increase in orders. This may be a shorter-term trade for some investors. However, younger consumers — who make up ThredUP's core market — are likely to remain budget-conscious for some time, which helps explain why analysts peg TDUP's consensus price target at $12.50, roughly 68% above its closing price on Dec. 1.
| 
